Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

BACKGROUND: Sorafenib and lenvatinib are first‐line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. METHODS: We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib between August 2009 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigesawa, Taku, Suda, Goki, Kimura, Megumi, Shimazaki, Tomoe, Maehara, Osamu, Yamada, Ren, Kitagataya, Takashi, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578287/
https://www.ncbi.nlm.nih.gov/pubmed/33102759
http://dx.doi.org/10.1002/jgh3.12339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578287/
https://www.ncbi.nlm.nih.gov/pubmed/33102759
http://dx.doi.org/10.1002/jgh3.12339

Ejemplares similares